Drugs / HMPL-A251
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07228247 | Dec 2025 → Nov 2028 expected | — | Hutchmed | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-23 | Hutchison Medipharma Limited | Results HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics hutch-med.com ↗
In vitro, the PI3K/PIKK inhibitor payload exhibited high potency, selectivity, and broad anti-tumor activity across a panel of 130 tumor cell lines. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-17 | Hutchison Medipharma Limited | HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors hutch-med.com ↗ |
| 2025-10-23 | Hutchison Medipharma Limited | HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics hutch-med.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HMPL-A251 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07228247 ↗ |
| Route | Intravenous | “All study participants will receive HMPL-A251 as IV infusion” NCT07228247 ↗ |